Biocon buys Viatris biosimilars for $3.3bn, eyes IPO

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost

Biocon annouces digital diabetes tie-up with Voluntis

Biocon has announced a deal with digital therapy specialist Voluntis, aiming to create personalised care for people with type 2 diabetes taking biosimilar insulins.

Mylan’s Lantus biosimilar held up by manufacturing issue

Amgen faces first Neulasta biosimilar rival as FDA approves ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic.

Biocon and Sandoz strike biosimilars partnership

Biosimilars firms Biocon and Sandoz have formed a worldwide partnership to develop the next generation of biosimilars in immunology and cancer.

FDA approves Mylan/Biocon Herceptin biosimilar

The FDA has approved Mylan and Biocon’s biosimilar of Roche’s Herceptin (trastuzumab) breast cancer drug after a delay because of manufacturing issues.